Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies.
Children and adolescents with severe or relapsing major depressive disorder (MDD) may require long-term antidepressant use, but safety and tolerability data on long-term treatment are limited. In a randomized, placebo-controlled trial in children and another in adolescents, vortioxetine and placebo...
| Publicado en: | European Child & Adolescent Psychiatry Vol. 34; no. 4; pp. 1425 - 1435 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Springer Nature
Apr2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |